• / Free eNewsletters & Magazine
  • / My Account


  1. How’s the Market Feeling These Days?

    GTx GTXI announced Thursday that the Data Safety Monitoring Board has given it the green light to proceed with Phase III trials for Acapodene. We're leaving our fair value estimate unchanged as we had anticipated a smooth interim review. In our opinion, Acapodene's potential exposure to generic ...

  2. America: The New Europe?

    GTx adds a European partner.

  3. When Flexibility Meets Opportunity in the European Commercial Real Estate Market

    We are raising GTx's fair value on recent positive Phase II trial results for Ostarine.

©2017 Morningstar Advisor. All right reserved.